| 13.04 3.64 (38.72%) | 11-05 12:08 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 15.18 |
1-year : | 17.73 |
| Resists | First : | 13 |
Second : | 15.18 |
| Pivot price | 10.49 |
|||
| Supports | First : | 10.66 |
Second : | 9.22 |
| MAs | MA(5) : | 10.31 |
MA(20) : | 10.53 |
| MA(100) : | 9.85 |
MA(250) : | 11.17 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 39 |
D(3) : | 20.3 |
| RSI | RSI(14): 71.2 |
|||
| 52-week | High : | 18.97 | Low : | 6.63 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ NPCE ] has closed above the upper band by 27.0%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 100.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 9.6 - 9.67 | 9.67 - 9.72 |
| Low: | 9.11 - 9.18 | 9.18 - 9.23 |
| Close: | 9.31 - 9.42 | 9.42 - 9.5 |
NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person and remotely. It sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. The company was incorporated in 1997 and is headquartered in Mountain View, California.
Wed, 05 Nov 2025
NeuroPace stock price target raised to $19 by Leerink on strong Q3 results - Investing.com
Wed, 05 Nov 2025
NeuroPace Inc.: Q3 Earnings Snapshot - CT Insider
Wed, 05 Nov 2025
NeuroPace Inc (NPCE) Q3 2025 Earnings Call Highlights: Record Revenue and Positive EBITDA Milestone - Investing.com Canada
Tue, 04 Nov 2025
NeuroPace, Inc. (NPCE) Reports Q3 Loss, Tops Revenue Estimates - Yahoo! Finance Canada
Tue, 04 Nov 2025
NeuroPace (Nasdaq: NPCE) raises revenue guidance to $97M–$98M on record results - Stock Titan
Tue, 04 Nov 2025
NeuroPace Inc.: Q3 Earnings Snapshot - theheraldreview.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 33 (M) |
| Shares Float | 23 (M) |
| Held by Insiders | 2.7 (%) |
| Held by Institutions | 91.5 (%) |
| Shares Short | 1,080 (K) |
| Shares Short P.Month | 945 (K) |
| EPS | -0.82 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.58 |
| Profit Margin | -29.3 % |
| Operating Margin | -29.1 % |
| Return on Assets (ttm) | -12.4 % |
| Return on Equity (ttm) | -177 % |
| Qtrly Rev. Growth | 22.1 % |
| Gross Profit (p.s.) | 2.02 |
| Sales Per Share | 2.67 |
| EBITDA (p.s.) | -0.6 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -16 (M) |
| Levered Free Cash Flow | -8 (M) |
| PE Ratio | -15.81 |
| PEG Ratio | 0 |
| Price to Book value | 21.96 |
| Price to Sales | 4.84 |
| Price to Cash Flow | -26.65 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|